C.Q. Pharmaceutical Holding Co., Ltd. (000950.SZ) Latest Company News

Oct 23, 2026, 10:33 UTC
Chongqing Pharmaceutical Holding reported revenue of 602.73 billion yuan and attributable net profit of 321 million yuan for the first three quarters of 2026, down 3.12% and 16.53% year over year, respectively.
Source:
- finance.sina.cn
Oct 23, 2026, 10:33 UTC
Chongqing Pharmaceutical Holding reported third-quarter 2026 revenue of 20.142 billion yuan, down 4.19% year over year, and attributable net profit of 66.0819 million yuan, down 35.05%.
Source:
- finance.sina.cn
Oct 8, 2026, 11:34 UTC
Chongqing Pharmaceutical (Group) Co., Ltd., a subsidiary controlled by Chongqing Pharmaceutical Co., Ltd., plans to register and issue perpetual notes of up to RMB 2.4 billion, subject to shareholder approval and regulatory registration.
Source:
- finance.sina.cn
Aug 25, 2026, 10:36 UTC
Chongqing Pharmaceutical Holding Co., Ltd. announced its first-half 2026 results: net profit attributable to shareholders was 254 million yuan, down 9.85% year-on-year, with revenue of 40.132 billion yuan, down 2.57%.
Source:
- finance.sina.cn
Aug 4, 2026, 09:14 UTC
Chongqing Pharmaceutical Holdings and its controlling subsidiaries have newly disclosed litigation and arbitration matters not previously disclosed within the past twelve months, with a total involved amount of 1.289 billion yuan, accounting for 11.17% of the company's most recent audited net assets attributable to the parent company.
Source:
- finance.sina.cn
Jul 23, 2026, 06:30 UTC
Chongqing Pharmaceutical Holding and Tangchuan Biotechnology Co., Ltd. signed a strategic cooperation agreement on the full functional sugar alcohol industry chain to jointly develop a full-cycle intestinal health product matrix.
Source:
- finance.sina.cn
Jul 23, 2026, 03:07 UTC
Chongqing Pharmaceutical Holding and Hansoh Pharmaceutical Group officially launched the Xinfengyi project strategic partnership, covering 9 provinces and municipalities, to integrate resources and deepen collaboration in market access and emerging businesses.
Source:
- finance.sina.cn

000950.SZ

Chongqing Pharmaceutical Holding reported revenue of 602.73 billion yuan and attributable net profit of 321 million yuan for the first three quarters of 2026, down 3.12% and 16.53% year over year, respectively.

Chongqing Pharmaceutical Holding reported third-quarter 2026 revenue of 20.142 billion yuan, down 4.19% year over year, and attributable net profit of 66.0819 million yuan, down 35.05%.

Chongqing Pharmaceutical (Group) Co., Ltd., a subsidiary controlled by Chongqing Pharmaceutical Co., Ltd., plans to register and issue perpetual notes of up to RMB 2.4 billion, subject to shareholder approval and regulatory registration.

Chongqing Pharmaceutical Holding Co., Ltd. announced its first-half 2026 results: net profit attributable to shareholders was 254 million yuan, down 9.85% year-on-year, with revenue of 40.132 billion yuan, down 2.57%.

Chongqing Pharmaceutical Holding and Tangchuan Biotechnology Co., Ltd. signed a strategic cooperation agreement on the full functional sugar alcohol industry chain to jointly develop a full-cycle intestinal health product matrix.

Chongqing Pharmaceutical Holding and Hansoh Pharmaceutical Group officially launched the Xinfengyi project strategic partnership, covering 9 provinces and municipalities, to integrate resources and deepen collaboration in market access and emerging businesses.